Atossa Therapeutics earnings were -$26.9M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest ATOS earnings report on Sep 30, 2024 announced Q3 2024 earnings of -$7.2M, up 19.5% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, ATOS reported annual earnings of -$30.1M, with 11.6% growth.
Atossa Therapeutics Earnings Reports & History FAQ
What were Atossa Therapeutics's earnings last quarter?
On ATOS's earnings call on Invalid Date, Atossa Therapeutics (NASDAQ: ATOS) reported Q3 2024 earnings per share (EPS) of -$0.06, up 20% year over year. Total ATOS earnings for the quarter were -$7.23 million. In the same quarter last year, Atossa Therapeutics's earnings per share (EPS) was -$0.05.
Is Atossa Therapeutics profitable or losing money?
As of the last Atossa Therapeutics earnings report, Atossa Therapeutics is currently losing money. Atossa Therapeutics's net profit (also called net income) for the twelve months ending Sep 30, 2024 was -$26.91 million, a 9.79% decrease year over year.
What was ATOS's earnings growth in the past year?
As of Atossa Therapeutics's earnings date in Invalid Date, Atossa Therapeutics's earnings has grown year over year. ATOS earnings in the past year totalled -$26.91 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.